Skip to main content
    C

    Curis Inc (CRIS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.44
    -0.01 (-2.07%)

    Market Cap: $2.97M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Curis Inc (CRIS) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Curis (CRIS) is expected to report earnings on Mar 17, 2027. In the quarter ended Sep 30, 2026, Curis reported EPS of -$1.94, above the -$2.29 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    53%(20/38)
    Avg Surprise
    -5.27%
    Streak
    2 Q

    Upcoming Estimates

    Reports Mar 17, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$2.98
    Range-$1.71 - $12.60
    6 analysts
    Revenue Consensus
    N/A
    RangeN/A
    6 analysts

    Next Report

    CRIS has an expected report date of Mar 17, 2027.

    CRIS Earnings Call

    The latest CRIS earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 38 quarters below that had an estimate, CRIS beat 20, missed 17 and matched 1. The widest gap in the table came in the quarter ended Mar 31, 2026, when EPS landed 331.03% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$1.94-$2.29-$2.29 - -$1.73+15.28%BeatN/A21 up, 0 downNov 12, 2026N/A
    Jun 30, 2026-$4.02-$5.70-$5.70 - -$4.40+29.47%BeatN/A32 up, 0 downAug 14, 2026N/A
    Mar 31, 2026-$25.00-$5.80-$7.80 - -$3.80-331.03%MissN/A20 up, 0 downMay 12, 2026N/A
    Dec 31, 2025-$9.95-$8.65-$14.40 - -$5.60-15.01%MissN/A40 up, 1 downMar 19, 2026$1.14M
    Sep 30, 2025-$9.80-$12.00-$14.80 - -$11.00+18.33%BeatN/A41 up, 1 downNov 6, 2025$3.18M
    Jun 30, 2025-$13.60-$30.30-$64.80 - -$16.20+55.12%BeatN/A41 up, 0 downAug 5, 2025$2.75M
    Mar 31, 2025-$25.00-$25.27-$27.80 - -$23.60+1.07%BeatN/A31 up, 0 downMay 6, 2025$2.38M
    Dec 31, 2024-$1.25-$0.99N/A-26.26%MissN/A32 up, 0 downMar 31, 2025$3.35M
    Sep 30, 2024-$34.00-$38.16-$42.20 - -$32.80+10.90%BeatN/A51 up, 0 downNov 14, 2024$2.93M
    Jun 30, 2024-$40.60-$36.20-$42.00 - -$14.60-12.15%MissN/A60 up, 0 downAug 1, 2024$2.55M
    Mar 31, 2024-$41.00-$42.44-$43.80 - -$41.60+3.39%BeatN/A50 up, 0 downMay 7, 2024$2.09M
    Dec 31, 2023-$40.60-$43.93-$46.40 - -$33.60+7.58%BeatN/A50 up, 0 downFeb 8, 2024$2.70M
    Sep 30, 2023-$42.60-$47.15-$56.00 - -$40.00+9.65%BeatN/A50 up, 0 downNov 2, 2023$2.83M
    Jun 30, 2023-$48.00-$47.00-$52.00 - -$40.00-2.13%MissN/A51 up, 0 downAug 3, 2023$2.20M
    Mar 31, 2023-$48.00-$43.00-$48.00 - -$32.00-11.63%MissN/A50 up, 0 downMay 4, 2023$2.30M
    Dec 31, 2022-$0.12-$0.13-$0.14 - -$0.10+7.69%BeatN/A50 up, 0 downMar 13, 2023$2.89M
    Sep 30, 2022-$56.00-$68.00-$68.00 - -$60.00+17.65%BeatN/A50 up, 0 downNov 9, 2022$2.83M
    Jun 30, 2022-$68.00-$66.00-$68.00 - -$64.00-3.03%MissN/A50 up, 0 downAug 4, 2022$2.39M
    Mar 31, 2022-$72.00-$64.00-$68.00 - -$60.00-12.50%MissN/A60 up, 0 downMay 5, 2022$2.06M
    Dec 31, 2021-$0.15-$0.13-$0.13 - -$0.12-15.38%MissN/A60 up, 0 downFeb 24, 2022$3.13M
    Sep 30, 2021-$48.00-$52.00-$52.00 - -$48.00+7.69%BeatN/A40 up, 0 downNov 9, 2021$3.04M
    Jun 30, 2021-$48.00-$44.00-$44.00 - -$44.00-9.09%MissN/A5N/AAug 3, 2021$2.29M
    Mar 31, 2021-$44.00-$37.00N/A-18.92%MissN/A4N/AMay 12, 2021$2.19M
    Dec 31, 2020-$0.11-$0.09-$0.12 - -$0.07-22.22%MissN/A4N/AMar 16, 2021$3.02M
    Sep 30, 2020-$44.00-$68.00-$68.00 - -$36.00+35.29%BeatN/A3N/ANov 10, 2020$2.74M
    Jun 30, 2020-$68.00-$80.00-$80.00 - -$64.00+15.00%BeatN/A3N/AAug 4, 2020$2.36M
    Mar 31, 2020-$0.28N/AN/AN/AN/AN/AN/AN/AMay 12, 2020$2.71M
    Dec 31, 2019-$5.20-$4.00N/A-30.00%MissN/AN/AN/AMar 19, 2020$3.29M
    Sep 30, 2019-$3.80-$4.00N/A+5.00%BeatN/AN/AN/ANov 5, 2019$2.86M
    Jun 30, 2019-$4.40-$3.80N/A-15.79%MissN/AN/AN/AAug 6, 2019$2.09M
    Mar 31, 2019-$6.00-$0.19N/AN/AN/AN/AN/AN/AMay 14, 2019$1.77M
    Dec 31, 2018-$72.00-$84.00-$84.00 - -$84.00+14.29%BeatN/A1N/AMar 26, 2019$2.75M
    Sep 30, 2018-$88.00-$122.67-$176.00 - -$96.00+28.26%BeatN/A4N/ANov 1, 2018$2.85M
    Jun 30, 2018-$104.00-$153.33-$172.00 - -$128.00+32.17%BeatN/A4N/AAug 2, 2018$2.36M
    Mar 31, 2018-$140.00-$140.00N/A0.00%In lineN/A3N/AMay 3, 2018$2.47M
    Dec 31, 2017-$0.25-$0.45-$0.50 - -$0.40+44.44%BeatN/A3N/AMar 8, 2018$3.26M
    Sep 30, 2017-$220.00-$186.67-$220.00 - -$140.00-17.86%MissN/A3N/ANov 7, 2017$2.44M
    Jun 30, 2017-$200.00-$186.67-$220.00 - -$160.00-7.14%MissN/A3N/AAug 3, 2017$2.06M
    Mar 31, 2017-$220.00-$173.33N/A-26.93%MissN/AN/AN/AMay 4, 2017$2.13M
    Dec 31, 2016-$0.40-$0.49N/A+18.37%BeatN/AN/AN/AMar 9, 2017$2.36M
    Last 40 quarters

    Estimates made before a stock split are shown on the same share basis as the reported EPS.

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$58.35, after -$116.85 the year before. It was -$340.75 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$58.35N/A
    Dec 31, 2024-$116.85N/A
    Dec 31, 2023-$179.20N/A
    Dec 31, 2022-$196.12N/A
    Dec 31, 2021-$140.15N/A
    Dec 31, 2020-$112.39N/A
    Dec 31, 2019-$19.40N/A
    Dec 31, 2018-$404.00N/A
    Dec 31, 2017-$640.25N/A
    Dec 31, 2016-$340.75N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 2,400 words across 6 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20262,3916
    2026Q1Mar 31, 20262,3578
    2025Q4Dec 31, 20252,7527
    2025Q3Sep 30, 20252,3467
    2025Q2Jun 30, 20254,20111
    2025Q1Mar 31, 20252,4548
    2024Q3Sep 30, 20243,6717
    2024Q2Jun 30, 20244,0008

    2026Q3 Earnings Call

    Opening remarks

    Diantha Duvall Host Thank you, and welcome to Curis' Third Quarter 2026 Business Update Call. Before we begin, I would like to encourage everyone to go to the Investors section of our website at www.curis.com to find our third quarter 2026 business update press release and related financial tables. I would also like to remind everyone that during the call, we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially. For additional details, please see our SEC filings. Joining me today are Jim Dentzer, President and Chief Executive Officer; Dr. Jonathan Zung, Chief Development Officer; and Dr. Ahmed Hamdy, Chief Medical Officer. We will also be available for a question-and-answer period at the end of the call. I'd now like to turn the call over to Jim.

    James Dentzer President and Chief Executive Officer Thank you, Diantha. Good afternoon, everyone, and welcome to Curis' third quarter business update call. I'll start with PCNSL, our lead program and first NHL study. We continue to make steady progress in our TakeAim Lymphoma Study in primary CNS lymphoma, one of the most rare and most difficult to treat of the NHL subtypes. As a reminder, the TakeAim Lymphoma Study is a registrational study of emavusertib in combination with ibrutinib in patients with relapsed/refractory PCNSL. We reported updated data this quarter for 7 BTK-naive patients and 39 salvage-line patients, patients whose disease had progressed while on treatment with a BTK inhibitor. The updated data show an 86% response rate in BTKi-naive patients, with 6 of 7 patients achieving a response. For context, it's important to note that published studies of BTK inhibitors in PCNSL have generally shown response rates of 39% to 67%. Clearly, the combination of emavusertib plus BTKi appears to be better than BTKi alone. For salvage-line patients, those patients whose disease had progressed while taking a BTK inhibitor, the updated data show a 26% response rate, with 10 of 39 patients responding when treated with the emavusertib plus BTKi combination after they had already progressed on BTKi monotherapy. For context, patients who have failed both frontline therapy and BTKi have a very poor prognosis, with many patients proceeding directly to hospice or best supportive care. That emavusertib is helping patients change that story and reverse their disease is very encouraging. In short, the updated data in both BTKi-naive and salvage-line patients provide further evidence of meaningful clinical activity and continue to support the potential for accelerated approval submissions in both the U.S. and Europe. We look forward to completing full enrollment in this registrational study on schedule in 2027.

    Frequently Asked Questions About CRIS

    When is Curis's next earnings date?

    Curis's next earnings report is expected for Mar 17, 2027.

    Did CRIS beat earnings estimates last quarter?

    Yes. Curis reported EPS of -$1.94 for the quarter ended Sep 30, 2026, above the -$2.29 estimate, a 15.28% surprise.

    What EPS do analysts expect from CRIS next quarter?

    The consensus EPS estimate for Curis for the quarter ending Dec 31, 2026 is $2.98 from 6 analysts, with estimates from -$1.71 to $12.60.

    How often does CRIS beat earnings estimates?

    Curis beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of -31.63%.